As per Divis Lab, it was informed by USFDA that it will lift the Import Alert 66-40 and will move to close out the warning letter issued to the company’s Unit-II at Chippada, Visakhapatnam.

Earlier this year in March, the USFDA issued an import alert under clauses 99-32 and 66-40 to the company’s Visakhapatnam unit following an audit between 29 November and December 6, 2016.

As per the information on the USFDA’s website, import alert 66-40 is issued to companies which do not comply with good manufacturing practices.

Read EquityPandit’s Technical Analysis on Nifty Pharma